| PFKP | phosphofructokinase, platelet type; 6-phosphofructo-2-kinase, platelet type |
|---|---|
| PM | after death (Lat. post mortem); after noon [Lat. post meridiem]; mean pressure; pacemaker; pantomogr... |
| IMDS | Idiopathic Myelo-Dysplastic Syndrome = Preleukemia = Refractory Anemi... |
| RA | 1) Refractory Anemia 2) Rheumatoid Arthritis ? Arthritis 3... |
| RAEB | Refractory Anemia with Excess of Blasts |
| immunologic | <immunology> Pertaining to immunology. (18 Nov 1997) |
|---|---|
| immunologic and biological factors | A collective grouping for biologically active substances that play a role in the functioning of the immune system and those that show biological or physiological activity. (12 Dec 1998) |
| immunologic capping | The process by which lymphoid cell surface immunoglobulin receptors, when exposed to bivalent anti-ig antibodies, collect in patches and form a cap at one pole of the cell. The caps may then be endocytosed or shed into the environment in the form of antigen-antibody complexes. Capping has also been induced by lectins and antigens. (12 Dec 1998) |
| immunologic deficiency syndromes | Syndromes in which there is a deficiency or defect in the mechanisms of immunity, either cellular or humoral. (12 Dec 1998) |
| immunologic diseases | Disorders caused by abnormal or absent immunologic mechanisms, whether humoral, cell-mediated or both. (12 Dec 1998) |
| immunologic factors | Biologically active substances whose activities affect or play a role in the functioning of the immune system. (12 Dec 1998) |
| immunologic high dose tolerance | Induction of tolerance by exposure to large amounts of protein antigens. (05 Mar 2000) |
| immunologic memory | <immunology> The ability to rapidly produce large quantities of specific immune cells after subsequent exposure to a previously encountered antigen. (09 Oct 1997) |
| immunologic pregnancy test | A general term for test's for detection of increased human chorionic gonadotropin in plasma or urine by immunologic techniques including latex particle agglutination, haemagglutination inhibition, radioimmunoassay, and radioreceptor assays. (05 Mar 2000) |
| immunologic surveillance | The theory that T-cells monitor cell surfaces and detect structural changes in the plasma membrane and/or surface antigens of virally or neoplastically transformed cells. (12 Dec 1998) |
| immunologic tests | Diagnostic techniques involving the demonstration or measurement of an immune response, including antibody production or assay, antigen-antibody reactions, serologic cross-reactivity, delayed hypersensitivity reactions, or heterogenetic responses. (12 Dec 1998) |
| immunologic tolerance | Lack of immune response to antigen. Theories of tolerance induction include clonal deletion and clonal anergy. In clonal deletion, the actual clone of cells is eliminated whereas in clonal anergy the cells are present but nonfunctional. Synonym: immunological tolerance, immunotolerance, nonresponder tolerance. (05 Mar 2000) |
| acquired platelet function defect | <haematology> Platelet function can be affected by a number of different disease processes including polycythaemia vera, leukaemia, myelofibrosis, renal failure, multiple myeloma and some medications (for example penicillins, salicylates, phenothiazines). Disturbed blood clotting can be manifested by: easy bruising, bleeding gums, nosebleeds, abnormal vaginal bleeding, rectal bleeding, skin rash, vomiting blood, coughing up blood or blood in the urine. A measure of bleeding time and coagulation profile will be part of the evaluation. (29 Dec 1997) |
| antigens, human platelet | Human alloantigens expressed only on platelets, specifically on platelet membrane glycoproteins. These platelet-specific antigens are immunogenic and can result in pathological reactions to transfusion therapy. (12 Dec 1998) |
| anti-platelet agents | Medications that, like aspirin, reduce the tendency of platelets in the blood to clump and clot. (12 Dec 1998) |